| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
26,020,000 |
| Market
Cap: |
214.67(M) |
| Last
Volume: |
6,675 |
Avg
Vol: |
6,621 |
| 52
Week Range: |
$3.99 - $8.45 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Home Health Care |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 7.1 |
| Insider 6 Months : 7.1 |
| Insider 3/6 Months : 14.6 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Fennec Pharmaceuticals is a biopharmaceutical company focused on the development of PEDMARK™ (sodium thiosulfate anhydrous injection) for the prevention of platinum-induced ototoxicity in pediatric cancer patients. Co. has licensed from Oregon Health & Science University intellectual property rights for the use of PEDMARK™ as a chemoprotectant and is developing PEDMARK™ as a protectant against the hearing loss caused by platinum-based anti-cancer agents in children.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
15,000 |
15,000 |
15,000 |
56,667 |
| Total Buy Value |
$104,601 |
$104,601 |
$104,601 |
$104,601 |
| Total People Bought |
1 |
1 |
1 |
3 |
| Total Buy Transactions |
2 |
2 |
2 |
4 |
| Total Shares Sold |
48,076 |
79,262 |
102,836 |
574,985 |
| Total Sell Value |
$313,377 |
$516,766 |
$650,404 |
$4,716,216 |
| Total People Sold |
2 |
2 |
2 |
4 |
| Total Sell Transactions |
5 |
9 |
19 |
49 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Raykov Rosty |
|
– • – |
2025-06-05 |
4 |
AS |
$7.78 |
$77,800 |
D/D |
(10,000) |
65,462 |
|
4% |
|
| Raykov Rosty |
|
– • – |
2025-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
5,208 |
75,462 |
|
- |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2025-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
2,431 |
160,951 |
|
- |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2025-05-22 |
4 |
OE |
$5.10 |
$41,922 |
D/D |
8,220 |
158,520 |
|
- |
|
| Hackman Jeffrey S. |
Chief Executive Officer |
• • – |
2025-05-19 |
4 |
B |
$6.99 |
$97,615 |
D/D |
13,965 |
15,000 |
0.01 |
8% |
|
| Raykov Rosty |
|
– • – |
2025-05-16 |
4 |
S |
$6.78 |
$113,002 |
D/D |
(16,667) |
70,254 |
|
-21% |
|
| Raykov Rosty |
|
– • – |
2025-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
33,334 |
86,921 |
|
- |
|
| Hackman Jeffrey S. |
Chief Executive Officer |
• • – |
2025-05-16 |
4 |
B |
$6.75 |
$6,986 |
D/D |
1,035 |
1,035 |
0.01 |
21% |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2025-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
16,667 |
150,300 |
|
- |
|
| Raykov Rosty |
|
– • – |
2025-05-05 |
4 |
AS |
$6.31 |
$63,100 |
D/D |
(10,000) |
53,587 |
|
31% |
|
| Raykov Rosty |
|
– • – |
2025-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,431 |
63,587 |
|
- |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2025-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
1,042 |
133,633 |
|
- |
|
| Rallis Chris A |
|
– • – |
2025-04-11 |
4 |
AS |
$4.95 |
$6,975 |
D/D |
(1,409) |
53,784 |
|
65% |
|
| Rallis Chris A |
|
– • – |
2025-04-11 |
4 |
OE |
$2.30 |
$4,998 |
D/D |
2,173 |
55,193 |
|
- |
|
| Raykov Rosty |
|
– • – |
2025-04-04 |
4 |
AS |
$5.25 |
$52,500 |
D/D |
(10,000) |
61,156 |
|
57% |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2025-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
1,042 |
132,591 |
|
- |
|
| Raykov Rosty |
|
– • – |
2025-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
2,431 |
71,156 |
|
- |
|
| Raykov Rosty |
|
– • – |
2025-03-05 |
4 |
AS |
$6.79 |
$67,900 |
D/D |
(10,000) |
68,725 |
|
22% |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2025-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
1,042 |
131,549 |
|
- |
|
| Raykov Rosty |
|
– • – |
2025-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
2,431 |
78,725 |
|
- |
|
| Rallis Chris A |
|
– • – |
2025-02-14 |
4 |
AS |
$6.82 |
$8,089 |
D/D |
(1,186) |
53,020 |
|
24% |
|
| Rallis Chris A |
|
– • – |
2025-02-14 |
4 |
OE |
$2.51 |
$5,000 |
D/D |
1,992 |
54,206 |
|
- |
|
| Raykov Rosty |
|
– • – |
2025-02-05 |
4 |
AS |
$6.66 |
$66,600 |
D/D |
(10,000) |
76,294 |
|
20% |
|
| Raykov Rosty |
|
– • – |
2025-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
2,431 |
86,294 |
|
- |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2025-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
1,042 |
130,507 |
|
- |
|
274 Records found
|
|
Page 1 of 11 |
|
|
0.03 (0.36%) 
